Research & Literature

Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease.

Umran RMR, Shukur ZYH

Modern rheumatology 2018; (28(1)):197-199 doi:10.3109/14397595.2015.1071234.

Incidence and Management of Glaucoma in Vogt Koyanagi Harada Disease.

Pandey A, Balekudaru S, Venkatramani DV, et al.

Journal of glaucoma 2016; (25(8)):674-80 doi:10.1097/IJG.0000000000000400.

Chronic Recurrent Vogt-Koyanagi-Harada Disease and Development of 'Sunset Glow Fundus' Predict Worse Retinal Sensitivity.

Abu El-Asrar AM, Al Mudhaiyan T, Al Najashi AA, et al.

Ocular immunology and inflammation 2017; (25(4)):475-485 doi:10.3109/09273948.2016.1139730.

Choroidal circulation impairment during the anterior recurrence of Vogt-Koyanagi-Harada disease confirmed with indocyanine green angiography and laser speckle flowgraphy.

Takemoto Y, Namba K, Mizuuchi K, et al.

Acta ophthalmologica 2016; (94(7)):e629-e636 doi:10.1111/aos.13024.

Vogt-Koyanagi-Harada disease.

O'Keefe GA, Rao NA

Survey of ophthalmology 2017; (62(1)):1-25 doi:10.1016/j.survophthal.2016.05.002.

Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.

Couto C, Schlaen A, Frick M, et al.

Ocular immunology and inflammation 2018; (26(3)):485-489 doi:10.1080/09273948.2016.1236969.

Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.

Herbort CP, Abu El Asrar AM, Yamamoto JH, et al.

International ophthalmology 2017; (37(6)):1383-1395 doi:10.1007/s10792-016-0395-0.

Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma.

Matsuo T, Yamasaki O

Clinical case reports 2017; (5(5)):694-700 doi:10.1002/ccr3.911.

Bilateral Iris Depigmentation and Ocular Hypotony as End-Stage Manifestations of Untreated Vogt-Koyanagi-Harada Disease.

Cuevas M, de-la-Torre A, Córdoba A

Ocular immunology and inflammation 2018; (26(7)):1101-1106 doi:10.1080/09273948.2017.1320411.

F-18 FDG PET Findings for Vogt-Koyanagi-Harada Disease.

Park HL, Yoo IR, Park SY

Nuclear medicine and molecular imaging 2017; (51(2)):190-192 doi:10.1007/s13139-015-0384-7.

Evaluation of Vestibular Functions in Patients with Vogt-Koyanagi-Harada Disease.

Fujiwara K, Morita S, Hoshino K, et al.

Audiology & neuro-otology 2017; (22(3)):190-195 doi:10.1159/000481426.

Increased Complement 3a Receptor is Associated with Behcet's disease and Vogt-Koyanagi-Harada disease.

Wang C, Cao S, Zhang D, et al.

Scientific reports 2017; (7(1)):15579 doi:10.1038/s41598-017-15740-8.

A Case of Vogt-Koyanagi-Harada Syndrome Mimicking Optic Neuritis.

Amir MM, Masood A, Khan Z

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2018; (28(4)):325-326 doi:10.29271/jcpsp.2018.04.325.

[A rare case of ocular scarrings in a patient with Vogt-Koyanagi-Harada disease].

Belmokhtar A, Daoudi R

The Pan African medical journal 2017; (28()):313 doi:10.11604/pamj.2017.28.313.4547.

Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease.

Herbort CP, Abu El Asrar AM, Takeuchi M, et al.

International ophthalmology 2019; (39(6)):1419-1425 doi:10.1007/s10792-018-0949-4.

A case of Vogt-Koyanagi-Harada disease as a sequela of drug reaction with eosinophilia and systemic symptoms.

Altman K, Shinohara M

JAAD case reports 2018; (4(9)):863-865 doi:10.1016/j.jdcr.2018.06.019.

The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy.

Huang Y, Fang S, Li D, et al.

Eye (London, England) 2019; (33(2)):176-182 doi:10.1038/s41433-018-0279-9.

Vogt-Koyanagi-Harada Disease, a Rare Entity in Spain: The Challenge of Worldwide Immigration and Globalization.

Fernández AB, Moyano SP, Husein-ElAhmed H, Juárez AMA

European journal of case reports in internal medicine 2018; (5(7)):000886 doi:10.12890/2018_000886.

Vogt-Koyanagi-Harada disease.

Street D, Sivaguru A, Sreekantam S, Mollan SP

Practical neurology 2019; (19(4)):364-367 doi:10.1136/practneurol-2018-002152.

Vogt-Koyanagi-Harada syndrome: what neurologists need to know.

Lueck CJ

Practical neurology 2019; (19(4)):278-281 doi:10.1136/practneurol-2018-002165.

Vogt-Koyanagi-Harada Disease and Birdshot Retinochoroidopathy, Similarities and Differences: A Glimpse into the Clinicopathology of Stromal Choroiditis, a Perspective and a Review.

Elahi S, Herbort CP

Klinische Monatsblatter fur Augenheilkunde 2019; (236(4)):492-510 doi:10.1055/a-0829-6763.

Initial misdiagnosis of Vogt-Koyanagi-Harada disease.

Shoughy SS, Tabbara KF

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society 2019; (33(1)):52-55 doi:10.1016/j.sjopt.2018.11.006.

Identification of Underlying Inflammation in Vogt-Koyanagi-Harada Disease with Sunset Glow Fundus by Multiple Analyses.

Murata T, Sako N, Takayama K, et al.

Journal of ophthalmology 2019; (2019()):3853794 doi:10.1155/2019/3853794.

A Case of Pneumatic Displacement with Gas Tamponade Performed for Macular Subretinal Hemorrhage Complicating Vogt-Koyanagi-Harada Disease.

Kobayashi T, Fukumoto M, Takai N, et al.

Case reports in ophthalmology 2020; (11(1)):143-150 doi:10.1159/000506436.

Early phase Vogt-Koyanagi-Harada Disease in Nepalese Elderly woman: A case report.

Bahadur BT, Gurung S, Singh S, Aryal M

Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH 2020; (12(23)):146-152 doi:10.3126/nepjoph.v12i1.26202.

BACILLARY LAYER DETACHMENT IN ACUTE VOGT-KOYANAGI-HARADA DISEASE: A Novel Swept-Source Optical Coherence Tomography Analysis.

Agarwal A, Freund KB, Kumar A, et al.

Retina (Philadelphia, Pa.) 2021; (41(4)):774-783 doi:10.1097/IAE.0000000000002914.

Evaluation of microvasculature alterations in convalescent Vogt-Koyanagi-Harada disease using optical coherence tomography angiography.

Fan S, Lin D, Hu J, et al.

Eye (London, England) 2021; (35(7)):1993-1998 doi:10.1038/s41433-020-01210-5.

Vogt-Koyanagi-Harada: treatment of recurrence after administration of 3 intravenous bolus of 1g of corticosteroids and mycophenolate mofetil.

Aguilar-González M, Martínez-López-Corell P, Marín-Payá E, et al.

Archivos de la Sociedad Espanola de Oftalmologia 2020; doi:10.1016/j.oftal.2020.06.033.

Melanin change of retinal pigment epithelium and choroid in the convalescent stage of Vogt-Koyanagi-Harada disease.

Huang Y, Yang YT, Lin B, et al.

International journal of ophthalmology 2020; (13(12)):1928-1932 doi:10.18240/ijo.2020.12.13.

VOGT-KOYANAGI-HARADA-LIKE UVEITIS FOLLOWED BY MELANOMA-ASSOCIATED RETINOPATHY WITH FOCAL CHORIORETINAL ATROPHY AND CHOROIDAL NEOVASCULARIZATION IN A PATIENT WITH METASTATIC CUTANEOUS MELANOMA.

Ng CC, Alsberge JB, Qian Y, et al.

Retinal cases & brief reports 2023; (17(1)):18-22 doi:10.1097/ICB.0000000000001113.

[Autofluorescence combined with spectral domain optical coherence tomography for diagnosis and follow-up of acute Vogt-Koyanagi-Harada disease].

Tian S, Yao J, Wang J, et al.

Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2021; (41(1)):135-140 doi:10.12122/j.issn.1673-4254.2021.01.20.

Vogt-Koyanagi-Harada Disease: A Case Series in a Tertiary Eye Center.

Shrestha P, Sharma S, Kharel R

Case reports in ophthalmological medicine 2021; (2021()):8848659 doi:10.1155/2021/8848659.

Vogt-Koyanagi-Harada disease is always bilateral: reports of unilateral cases failed to use choroidal investigations showing subclinical involvement of the fellow eye.

Papasavvas I, Herbort CP

Journal of ophthalmic inflammation and infection 2021; (11(1)):6 doi:10.1186/s12348-021-00237-3.

Iris Manifestations in Inadequately Treated Chronic Recurrent Vogt-Koyanagi-Harada Disease.

Chee SP, Win MZA

Ocular immunology and inflammation 2022; (30(5)):1116-1122 doi:10.1080/09273948.2020.1870701.

Delayed-onset unilateral Vogt-Koyanagi-Harada syndrome: a multimodal imaging appraisal.

Verma S, Thakur H, Azad SV, Kumar V

BMJ case reports 2021; (14(2)) doi:10.1136/bcr-2020-238623.

Classification Criteria for Vogt-Koyanagi-Harada Disease.

American journal of ophthalmology 2021; (228()):205-211 doi:10.1016/j.ajo.2021.03.036.

Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review.

Herbort CP, Tugal-Tutkun I, Abu-El-Asrar A, et al.

Eye (London, England) 2022; (36(1)):29-43 doi:10.1038/s41433-021-01573-3.

Long-term Outcomes of Uveitis Associated with Vogt-Koyanagi-Harada Disease in the Pediatric Age Group.

AlBloushi AF, AlEnezi SH, Al Owaifeer AM, et al.

Ocular immunology and inflammation 2022; (30(7-8)):1669-1677 doi:10.1080/09273948.2021.1933074.

Vogt Koyanagi Harada syndrome in a 15-year-old girl, steroids side effects and recurrences.

Yıldırım G, Çavdarlı C, Özdemir EY, Alp MN

The Turkish journal of pediatrics 2021; (63(3)):527-532.

Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.

Monferrer-Adsuara C, Hernández-Bel L, Hernández-Garfella ML, et al.

Optometry and vision science : official publication of the American Academy of Optometry 2021; (98(11)):1309-1316 doi:10.1097/OPX.0000000000001798.

Vogt-Koyanagi-Harada disease.

Joye A, Suhler E

Current opinion in ophthalmology 2021; (32(6)):574-582 doi:10.1097/ICU.0000000000000809.

Vogt-Koyanagi-Harada: treatment of recurrence after administration of 3 intravenous bolus of 1 g of corticosteroids and mycophenolate mofetil.

Aguilar-González M, Martínez-López-Corell P, Marín-Payá E, et al.

Archivos de la Sociedad Espanola de Oftalmologia 2021; (96(11)):593-597 doi:10.1016/j.oftale.2020.06.027.

Vogt-Koyanagi-Harada Syndrome: A Diagnostic Conundrum.

Hussain A, Khurana R

Cureus 2021; (13(12)):e20138 doi:10.7759/cureus.20138.

A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy.

Minami K, Egawa M, Kajita K, et al.

Case reports in ophthalmology 2021; (12(3)):952-960 doi:10.1159/000520416.

OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY REVEALS PARADOXICALLY DECREASING CHOROIDAL THICKNESS AND INCREASING BLOOD FLOW IN REMITTING VOGT-KOYANAGI-HARADA SYNDROME.

Fayed AE, Gerges TK

Retina (Philadelphia, Pa.) 2022; (42(9)):1788-1795 doi:10.1097/IAE.0000000000003525.

Case of probable Vogt-Koyanagi-Harada syndrome: A rare presentation.

Mehta KN, Daigavane S

Indian journal of ophthalmology 2022; (70(7)):2684-2686 doi:10.4103/ijo.IJO_495_22.

EFFICACY OF COMBINED SYSTEMIC CORTICOSTEROID AND EARLY IMMUNOMODULATORY THERAPY WITHIN THREE MONTHS OF ONSET IN VOGT-KOYANAGI-HARADA DISEASE.

Park HS, Park HY, Lee CS, et al.

Retina (Philadelphia, Pa.) 2022; (42(12)):2361-2367 doi:10.1097/IAE.0000000000003617.

Impact of Initial Management on Disease Evolution in Vogt-Koyanagi-Harada Syndrome: A Retrospective Cohort of 50 Patients.

Fauquier A, Barba T, Hot A, et al.

Ocular immunology and inflammation 2024; (32(4)):402-406 doi:10.1080/09273948.2023.2206485.

Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.

Vukojević M, Vukojevic N, Vuković A, et al.

Acta dermatovenerologica Croatica : ADC 2023; (31(4)):229-231.

Vogt-Koyanagi-Harada disease after SARS-CoV-2 infection: Case report and literature review.

Zou H, Zhang K, Chen X, Sha S

Immunity, inflammation and disease 2024; (12(4)):e1250 doi:10.1002/iid3.1250.

Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.

Acharya NR, Rathinam SR, Thundikandy R, et al.

American journal of ophthalmology 2024; (267()):100-111 doi:10.1016/j.ajo.2024.06.004.

The Incidence and Presentation Features of Glaucoma in Vogt-Koyanagi-Harada Syndrome: A Systematic Review and Meta-Analysis.

Abdelaal A, Hassan AR, Katamesh BE, et al.

Ophthalmology. Glaucoma 2024; (7(6)):587-601 doi:10.1016/j.ogla.2024.06.005.

Common practice patterns in the diagnosis and management of Vogt-Koyanagi-Harada syndrome: a survey study of uveitis specialists.

Choo CH, Acharya NR, Shantha JG

Frontiers in ophthalmology 2023; (3()):1217711 doi:10.3389/fopht.2023.1217711.

Early and Late Treatment Influence on Chorioretinal Microvasculature in Vogt-Koyanagi-Harada Patients Using Optical Coherence Tomography Angiography.

Huang F, Tan S, Hu J, et al.

Translational vision science & technology 2024; (13(8)):15 doi:10.1167/tvst.13.8.15.

A Case Report and Literature Review of Vogt-Koyanagi-Harada-Like Uveitis Secondary to Dabrafenib and Trametinib: 4-Year Follow-Up Using Retinal Multimodal Imaging.

Ucan Gunduz G, Gullulu ZZ, Nizam Tekcan S, et al.

Ocular immunology and inflammation 2024; (32(10)):2589-2593 doi:10.1080/09273948.2024.2401626.

Evaluation of the Activity of Vogt-Koyanagi-Harada Disease; A Comparison of Indocyanine Green Angiography Scoring, Enhanced Depth Imaging Optical Coherence Tomography, and Choroidal Vascularity Index.

Fadakar K, Rezaii K, Niktinat H, et al.

Journal of current ophthalmology 2024; (36(1)):66-71 doi:10.4103/joco.joco_156_23.

Retromode Infrared Scanning Laser Ophthalmoscopy in Vogt-Koyanagi-Harada Disease.

Yasuda S, Yoshida T, Suzuki Y, et al.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2025; (263(4)):1089-1103 doi:10.1007/s00417-024-06693-6.

A Case of Vogt-Koyanagi-Harada Disease: Diagnosis Based on the Presence of Vitiligo and Sunset Glow Fundus Without Ocular Symptoms.

Tsutsui H, Fukuda K, Nakajima I, Yamashiro K

Cureus 2025; (17(1)):e78209 doi:10.7759/cureus.78209.

Vogt-Koyanagi-Harada disease in a patient with retinitis pigmentosa in one eye and pigmented paravenous retinochoroidal atrophy in the other eye.

Sato J, Hashizume K, Nishida Y, et al.

American journal of ophthalmology case reports 2025; (38()):102298 doi:10.1016/j.ajoc.2025.102298.

Efficacy of azathioprine as a first-line therapy in new onset of acute Vogt-Koyanagi-Harada disease in the Indian population.

Parchand SM, Saraogi T, Chatterjee S, et al.

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society 2025; (39(1)):65-70 doi:10.4103/sjopt.sjopt_200_23.

Predictive Factors for Uveitis Refractory to Treatment in Initial-Onset Acute Vogt-Koyanagi-Harada Disease.

Gin TJ, Surendran SA, Rogers SL, Lim LL

Clinical & experimental ophthalmology 2025; (53(6)):627-636 doi:10.1111/ceo.14538.

Long-Term Outcomes of Pediatric Vogt-Koyanagi-Harada Disease.

AlQahtani DS, Almutairi AH, Ababtain IS, et al.

Ocular immunology and inflammation 2025; (33(10)):2257-2264 doi:10.1080/09273948.2025.2491562.

Acute phase Vogt-Koyanagi-Harada syndrome resistant to corticosteroid therapy in an adult female patient.

Kurt ZE, Argin MA

Archivos de la Sociedad Espanola de Oftalmologia 2025; (100(11)):723-727 doi:10.1016/j.oftale.2025.08.003.

Clinical characteristics and long-term outcomes of Vogt-Koyanagi-Harada disease in pediatric age group.

Bezci Aygun F, Akgoz Koyuncuoglu M, Kadayıfcılar S, Ozen S

BMC ophthalmology 2025; (25(1)):509 doi:10.1186/s12886-025-04334-y.

Efficacy of Tumor Necrosis Factor-α Inhibitor Adalimumab in Chronic Recurrent Vogt-Koyanagi-Harada Disease.

Lee J, Chung YR, Kim HR, Song JH

Pharmaceuticals (Basel, Switzerland) 2025; (18(12)) doi:10.3390/ph18121848.